人工重组肺泡表面活性剂（ＡＰＳ）是基于成人呼吸窘迫综合征（ＡＲＤＳ）发病中存在的肺泡表面活性剂缺乏和过量自由基引起肺损伤两种主要发病因素设计研制的。内毒素致ＡＲＤＳ大鼠的预防给药试验结果表明，ＡＰＳ能显著降低动物死亡率（４６４７％→１６１７％）和肺水肿程度（Ｗ／Ｄ从５５５→４８４）。同时，肺灌洗液的表面性能也有明显改善（平衡表面张力从６１８６→４７０２ｍＮ·ｍ－１，正常４３９４ｍＮ·ｍ－１；最小表面张力从３０４１→７１６ｍＮ·ｍ－１，正常３４９ｍＮ·ｍ－１）。动物初步预防试验的结果支持ＡＲＤＳ防治药物设计依据。 Artificial recombinant alveolar surfactant (APS) was developed based on two major risk factors of alveolar surfactant deficiency and excessive free radical-induced lung injury in the pathogenesis of adult respiratory distress syndrome (ARDS). The results of prophylactic administration of endotoxin-induced ARDS rats showed that APS significantly reduced animal mortality (4647% → 1617%) and pulmonary edema (W / D from 5.55 ~ 4.84). At the same time, the surface properties of lung lavage fluid also improved significantly (equilibrium surface tension ranged from 6186 → 4702 mN · m-1 to normal range of 4394 mN · m-1; the minimum surface tension ranged from 3041 to 716 mN · m-1, normal 3.49 mN · m-1). The results of animal preliminary prevention trials support ARDS prevention and treatment of drug design basis.